Research into novel treatments for Chagas disease has gained significant momentum in recent years with public-private partnerships, pharmaceutical companies and research organizations providing resources and funding to tackle the issue of neglected diseases as a collective responsibility [201] and an increasingly global problem [1] . Repurposing existing drugs has been the quickest way to fill the late-stage discovery and clinical pipelines for trypanosomatid disease indications in an effort to bring forward treatments to those in need in the most expedient manner [2, 3] . For Trypanosoma cruzi (Tc) drug research, azole antifungal CYP51 inhibitors and heterocyclic nitro compounds have proven efficacious in preclinical models of Tc infection [3] [4] [5] [6] [7] [8] [9] [10] [11] and are clinically validated for other indications [12] . Posaconazole and a prodrug of ravuconazole (E1224) are the first compounds to enter clinical trials for Chagas disease in 40 years [13] and the outcomes of these trials will be available later this year. Further characterization of benznidazole continues in the clinic in the BENEFIT trial, investigating the treatment of chronically infected patients with cardiomyopathy [202] , and the results of a 10-year follow-up study of benznidazole-treated chronically infected patients (TRAEANA) are due this year [203] . The BERENICE project is a preclinical study investigating the use of lipid formulations to improve pharmacokinetic and pharmacodynamic properties of drugs with trypanocidal activity to obtain a more effective treatment [204] . Preclinical molecules in the public domain are K777, a cruzipain inhibitor [2] , and new chemical entities from the fenarimol series of compounds [14, 15] that are non-azole, Tc CYP51 inhibitors in development by the Drugs for Neglected Diseases initiative [205] .
Desperate need does not guarantee success however, and from a discovery perspective the pipeline is rather thin. Discovery efforts to identify new chemical entities must be fed with hits to evaluate and progress as an insurance against late-stage failure. Furthermore, diversity in mode of action will broaden treatment options and enable the issues of drug resistance [16, 17] and strain or Discrete Typing Unit sensitivity [18] [19] [20] to be tackled more effectively.
In 2009, a luminescence cell-based microorganism primary high-throughput screen (HTS) to identify inhibitors of Tc replication was conducted at the BROAD Institute and the results published on PubChem [206] . Compounds were screened for the ability to inhibit intracellular trypanosomes replicating inside host cells using modified Tc parasites expressing b-galactosidase. Parasites remaining after treatment with test compounds can be detected by a luminescent reporter system (GalScreen ® ) after cell lysis. The screening protocol provides a 'catch-all' method of identifying compounds that kill Tc, inhibit cell invasion or inhibit parasite development inside the cell.
Over 300,000 compounds were screened and more than 4000 actives identified, a hit rate of Selection and optimization of hits from a high-throughput phenotypic screen against
Trypanosoma cruzi
Background: Inhibitors of Trypanosoma cruzi with novel mechanisms of action are urgently required to diversify the current clinical and preclinical pipelines. Increasing the number and diversity of hits available for assessment at the beginning of the discovery process will help to achieve this aim. Results: We report the evaluation of multiple hits generated from a high-throughput screen to identify inhibitors of T. cruzi and from these studies the discovery of two novel series currently in lead optimization. Lead compounds from these series potently and selectively inhibit growth of T. cruzi in vitro and the most advanced compound is orally active in a subchronic mouse model of T. cruzi infection. Conclusion: High-throughput screening of novel compound collections has an important role to play in diversifying the trypanosomatid drug discovery portfolio. A new T. cruzi inhibitor series with good drug-like properties and promising in vivo efficacy has been identified through this process. approximately 1.4% [207] . This article will report the results of the HTS follow-up work and the outcome of early lead optimization studies focused on two promising Tc inhibitor series identified from the screen. Pharmacokinetic profiles and the results of in vivo efficacy studies in a model of Tc infection are presented. Hits for human African trypanosomiasis (HAT) and Leishmaniasis identified by extended profiling of our developing compound library will also be reported.
Results

Hit triage
Triaging a large data set to give a manageable number of starting points is time consuming
ReseaRch aRticle | Keenan and subjective, even with the aid of computational techniques. From 4063 screen actives, the first filter selected for the most active hits (Tc IC 50 <1 µM; selectivity index (SI) >10 = 1689 hits) and the second filter excluded charged molecules (485 compounds) as well as molecules containing reactive functional groups (313 compounds) leaving 891 hits. A clustering protocol was applied that provided a list of 354 clusters varying in composition for further ana lysis (Clusters determined by application of Pipeline Pilot™ protocol FCFP_6). The number of clusters containing singletons was quite high after this manipulation. The clusters were examined by three medicinal chemists, which naturally provided three distinct lists of preferred clusters with varying degrees of overlap. Simple and subjective manual ana lysis of the clusters showed that they were relatively unrepresentative of compound substructures.
Re-ana lysis of the 891 preclustered hits by reduction back to a core scaffold (substructure searching) de-emphasized nuisance side-chains such as long-chain polyamines, and re-emphasized low-molecular-weight drug-like scaffolds as desirable start points for hit elaboration. This process also served to decrease the number of clusters for follow up to 75, with a much lower number of compounds identified as singletons.
Compounds were selected for in-house followup screening on the basis of activity within the cluster, molecular weight, evidence of cluster Structure-activity relationship (SAR) trends and synthetic tractability, and selected against on the basis of high lipophilicity, flat SAR within the cluster and good activity dependent on undesirable structural motifs. From a list of 170 compounds identified for rescreening, 123 were sourced, purchased and assayed in-house in a medium-throughput Tc screen analogous to the high-throughput version used to generate the hits. In-house hit confirmation screening removed approximately half of the purchased compounds, with 60 returning an IC 50 < 1 µM (see supplementaRy data for Tc inhibition activity data). A total of 15 representative lead structures of these substructure clusters are shown in FiguRe 1 . The associated Tc inhibition activity and cytotoxicity data are shown in table 1, together with standard comparator compounds benznidazole and posaconazole. From start to finish the hit selection and confirmation process took approximately 10 months to complete and to arrive at the point that hit assessment could take place.
Hit evaluation A priority list for evaluation was determined from the set of 15 hit-to-lead starting points. Compounds homologous to known antifungal pharmacophores with antitrypanosomal activity, and other compounds likely to be Tc CYP51 inhibitors on comparison with in-house discovery efforts [15] and our interpretation of a CYP51 pharmacophore (an assessment made on the basis of a compound containing a basic heterocycle and two additional lipophilic or aromatic motifs in a trigonal or tetrahedral arrangement around a central atom) were put at the end of the list of compounds to be investigated (e.g., CM16, CM29, CM42). Compounds with structures novel to the field were favored even if they were less active. The first phase of the evaluation plan sought to confirm activity in more than one analog of the hit, assess synthetic tractability, determine the extent to which structural domains influenced activity and identify key pharmacophores. Applying these evaluation criteria to the list of 15 hits, six series were brought to a rapid conclusion: CM83, CM91, CM101 (only the starting hit was active); CM13 (synthetically intractable); CM97 (resynthesized parent hit inactive) and CM2 (physicochemical concerns raised); and one series was not worked on CM81. Investigation of CM3, CM90 & CID4135073 Series CM3 looked quite promising early on in the evaluation process and a longer time was spent working through the SAR. An initial 20-fold increase in activity was obtained by extending heteroaromatic ring A into chemical space (1, FiguRe 2 ). However, attempts to manipulate other structural domains for improved activity failed and the SAR was essentially flat (supplementaRy data).
Evaluation of CM90 was refocused at the beginning of the hit assessment process as a result of rechecking the BROAD screen library for analogs, in order to extract additional SAR data. A close and more active analog, CID4135073 (Hit 16) was identified (FiguRe 3), which had been excluded from the rescreening stage of the hit confirmation process due to a lack of commercial availability. The compound was resynthesized and the low nM activity in vitro confirmed (Tc IC 50 : 30 nM; L6 IC 50 : 66 µM). The cytotoxicity was also lower, offering an opportunity to move away from a potential cellular toxicity issue that was quite prevalent in the CM90 series.
The results of the Hit 16 SAR investigations are summarized in FiguRe 3 . Briefly, the imidazole could not be replaced with simple saturated rings such as pyrrolidine, or carry any C2-alkyl groups without losing activity, suggesting access to the basic nitrogen atom was important for activity. Methylation of hydroxyl-1 increased activity (Tc IC 50 : 12 nM) and chiral resolution of the corresponding ethyoxy analog (2) showed activity resided in one enantiomer ([E1] Tc IC 50 : 16 nM; [E2] >100 nM). Suitable cyclic replacements of the 1,2-diol fragment were not active (e.g., piperazine or morpholine), while all replacements of the 6-bromo-2-naphthyl group were either much less active (>100-fold) or inactive.
Investigation of CM82 & CM74
An opportunity to rationally progress the Hit 16 SAR into alternative chemical space was desired, thus the hit-list (FiguRe 1 ) was revisited to identify scaffolds that could be related to this compound. Simplistic pharmacophore mapping examining distances between molecular features (basic centre -hydrogen-bond acceptor -lipophilic moiety) identified compounds CM82 and CM74 as two hits that could support a scaffold hop approach.
The investigation of CM82 was efficient and short-lived (FiguRe 4) FiguRe 3 ), which was consistent amongst the small number of compounds profiled.
The investigation of CM74 has been more extensive and the series is now one of two that has progressed into the lead optimization phase. The initial SAR trends were determined on the 1,3-substituted phenyl hit scaffold investigating changes in the anilino R-group (SAR domain D) and aromatic rings B and C in the first instance. The R-group was easy to manipulate and a restriction of substituent size was established early on, turning out to be a useful way to confine the SAR options for modification at this position. Branched alkyl amides, lower alkyl and lower alkyl sulfonamides showed up to a twofold improvement in activity (FiguRe 5b). Switching aromatic ring B to 3-pyridyl added an additional twofold activity improvement to amido (8) and sulfonamido (10) analogs, but the activity of the ethyl derivative (9) dropped away significantly improving in vitro activity and also stability towards oxidative metabolism by liver microsomes (table 2) . Sulfonamide analog 26 Tc IC 50 : 0.1 nM is the most active analog assessed in our in-house assay. The activity is reproducible across different compound batches and 26 is the lead compound in a small series of derivatives with IC 50 < 1 nM (analogs not shown). Lead optimization studies are ongoing with this series.
CM82
Investigation of CM100
The second successful hit assessment effort was focused on CM100. Compound CM100 is a trisubstituted aromatic ring with a substructure surprisingly under represented in the literature. Four SAR domains are clearly identified (FiguRe 7a-d) , and the majority of the preliminary work was focused on domain D (as the quickest to investigate) and domain C (replacement of the ester in preparation for obtaining oral activity).
Optimization of domain D provided big gains in activity. In the first instance, a simple substituted phenyl SAR study did not pick up any additional binding interactions of note, although activity did improve two-threefold over the starting hit on addition of 3,4-Cl and 4-CF 3 substituents. Introduction of a 2-phenyl-5-pyrimidinyl moiety provided a significant step forward in activity (30, Tc IC 50 3 nM). Further investigations of the pyrimidine ring suggest the N-atom(s) make an advantageous binding interaction that can be accessed by other heterocyclic rings with a correctly placed heteroatom, including 3-pyridine, 2-pyrazine, 2-thiophene and 5-thiazole. For the early analogs, the ester (domain C ) was critical for activity and a key focus was to find a more hydrolytically stable replacement to help achieve good plasma exposure following oral administration. The results of this SAR study with compounds containing optimized domain D biaryl moieties are shown in FiguRe 7b . Potent activity was obtained with sulfonamide 31, oximes 34 and 42, and nitrile 40. To challenge the requirement for a hydrogen bond acceptor at this position, a series of alkyl analogs were prepared. The low nM activities obtained for these compounds (36, 38, 44 & 45) show that a degree of space filling by the substituent is equally sufficient to produce very potent analogs.
With the ester replaced, the biaryl moiety was re-optimized on several of the most interesting new scaffolds with the goal of producing compounds suitable for evaluation in oral exposure studies and in vivo efficacy testing. The oxime series is shown in FiguRe 7c . SAR trends observed for the biaryl moiety with earlier analogs are further exemplified by this optimized set, such that the correct positioning of a heteroatom in aromatic ring E and the correct regiochemical placement of aromatic ring F give the most potent analogs. Lead optimization studies continue with this series.
Physicochemical, in vitro pharmacokinetic & selectivity assays
In parallel with activity assessment, new analogs of interest across all series were screened for solubility, stability towards oxidative metabolism by human liver microsomes (in vitro data scaled to predict the human clearance and hepatic extraction ratio [EH] ) and ability to inhibit CYP3A4 (an important drug metabolizing enzyme). With routine measurement of these parameters, any potential physicochemical, pharmacokinetic or selectivity issues that needed to be improved during lead optimization were identified early and could be addressed with an appropriate SAR strategy. Data for representative SAR analogs from the two lead series, CM74 and CM100, are shown in tables 2 & 3, respectively.
In the CM74 series (table 2) a clear pattern of increasing stability towards oxidative metabolism (decreasing EH) is seen on switching from the 1,3-substituted phenyl core to the 1,4-substituted phenyl core, and from 3-pyridine to 4/5-imidazole. This trend holds across different anilino-R groups. Solubility of the free Table 2 . In vitro physicochemical and metabolic profiles of lead compounds from the CM74 series. Selection & optimization of hits from a high-throughput phenotypic screen against T. cruzi | ReseaRch aRticle www.future-science.com base at pH 6.5 in phosphate buffer is low, but is improved with the pendent glycine group (17) and also by preparation of the hydrochloride salt (data not shown). LogD and inhibition of CYP3A4 are variable.
Profiling of analogs prepared in the early stages of the CM100 series (table 3) showed that the extent of metabolism by microsomes was dependent on either the domain C moiety (hydrogen-bond acceptor) or the domain D ReseaRch aRticle | Keenan moiety (biaryl) and optimization of both was required during the SAR studies. Lead compounds containing an oxime or nitrile in combination with 2-phenyl-5-pyrimidine or 2-phenyl-1,3-thiazole fragments were optimal with respect to maintaining good Tc inhibition and stability towards oxidative metabolism. Solubility at pH 6.5 is again low and this is a key parameter to improve during lead optimization. Log D is within a drug-like range and the propensity to inhibit CYP3A4 depends upon the biaryl moiety and can therefore be controlled.
In vivo evaluation
Oral exposure
The plasma exposure levels of the leading compounds across a number of the hit series was measured in mice following oral administration, as a forerunner to proof-of-concept in vivo efficacy testing. Compounds from the CM100 lead series are shown as an example (FiguRe 8 
Efficacy in a subchronic model of Tc infection
The in vivo efficacy of lead compounds from several of the most promising hit series was and 56 from the CM100 series were able to reduce parasitemia to negligible levels after 20 days of dosing, but parasites were detected in blood for 56 during the 10-day rest period and for 40 and 42 after three cycles of immuno suppression.
Encouragingly, one mouse in the group treated with compound 34 was parasite free after three cycles of immunosuppression, although not cured as determined by PCR of targeted organs (data not shown). The study of 34 was repeated and a variation in the dosing regimen was included. Two groups of mice were dosed with 34 either 20 mg/kg twice daily (b.i.d.) or 50 mg/kg q.d. Benznidazole dosed at 100 mg/ kg q.d. was included as a positive control. The outcome of the study is shown in FiguRe 9 and summarized in table 4.
Treatment with compound 34 (20 mg/kg, b.i.d.) reduced parasitemia to negligible levels over the 20-day dosing period in four out of five mice. Following one cycle of immunosuppression (q.d. treatment with 50 mg/kg cyclophosphamide for 4 days, followed by 3 days rest), parasite rebound was observed in one out of the four remaining mice, and therefore only three mice received the next two cycles of immunosuppression. After completion of all three immunosuppression cycles, the remaining three animals were negative for parasitemia in blood, and organs were taken for PCR ana lysis. Parasites were detected in all of the remaining mice but not in all tissues: skeletal muscle (mouse 1); spleen (mouse 4); colon (mice 4 and 5). Treatment with compound 34 (50 mg/kg, q.d.) was not as effective as the lower dose given more frequently, suggesting that maintaining concentrations across the full dosing interval is important for efficacy. The control drug benznidazole performed as expected with 80% of mice surviving until experiment end, but without cure. Vehicletreated mice maintained high levels of blood parasitemia and were sacrificed at day 14.
Screening of hit series for HAT & leishmaniasis
The influx of new analogs into the in-house compound library facilitated a small-scale, opportunistic screening effort in search of new hits for HAT (Trypanosoma brucei rhodesiense) and leishmaniasis (Leishmania infantum). With the libraries biased towards Tc inhibitors the chance of finding something was low, but worth investigating nonetheless. This activity was continued throughout the early hit assessment phase until a representative structural cross-section of Tc active and inactive compounds had been profiled.
Two series were identified as potential hits against both HAT and leishmaniasis targets, CM101 and Hit 16 (FiguRe 3) . The CM101 series was not progressed for Tc as no active analogs were prepared, but the screening of these compounds against HAT found weak activity across the series (IC 50 < 5 µM) (table 5).
Compound 57 was also active in vitro against L. infantum (IC 50 2.16 µM), and other close analogs of this compound have similar levels of activity against this target giving confidence the activity is real. The CM101 series is a potentially interesting starting point for hit assessment for either a HAT or leishmaniasis effort as the molecules bear a structural resemblance to N-myristoyl transferase inhibitors reported to cure a stage 1 HAT infection [21] [22] [23] .
Saturated, heterocyclic replacements of imidazole prepared as part of the Hit 16 hit assessment process (FiguRe 3) , inactive against Tc, were active in HAT and leishmaniasis profiling screens. Compound 60 was identified as a potent inhibitor of T. b. rhodesiense and L. infantum, and the leading hit amongst a series of analogs (table 6) . In vitro cellular toxicity is an issue for this series and ongoing SAR studies are directed towards improving the selectivity index.
Experimental
General synthetic & analytical chemistry methods Hits identified for rescreening were purchased from commercial suppliers and used without further purification or re-ana lysis. Synthetic routes used for the general elaboration of hit series are found in the supporting information. Reagents were purchased from commercial suppliers and used without further purification. Commercially available anhydrous solvents were used and stored under nitrogen, unless indicated otherwise. Reactions involving moisture-sensitive reagents were conducted under an atmosphere of dry nitrogen in glassware dried with a heat-gun. TLC using silica gel Merck 60 F254 plates and detection with UV light was used to monitor reactions. 
Preparation of N-(2-(1H-imidazol-1-yl)-5-[(1E)-N-methoxyethanimidoyl]phenyl)-2-phenylpyrimidine-5-carboxamide (34)
4´-fluoro-3´-nitroacetophenone (10 g, 0.054 mol) was dissolved in N,N-dimethylformamide (50 ml) and K 2 CO 3 (9.05 g; 0.065 mol) and imidazole (7.44 g; 0.11 mol) were added and the mixture was heated at 60°C for 3 h. The reaction was poured onto water (150 ml) and extracted with EtOAc (3 × 50 ml). The organics were combined, washed with water (50 ml), brine (30 ml), dried (MgSO 4 ), filtered and concentrated to give E1 as a purple powder (9.93 g; 3H) . E1 (9.93 g, 0.043 mol) was dissolved in a mixture of ethanol (100 ml) and water (30 ml). Iron powder (4.79 g; 0.086 mol) and ammonium chloride (9.19 g; 0.172 mol) were added to the mixture and it was stirred at 60°C for 3 h and then at room temperature for 48 h. The mixture was then heated to 50°C before filtering through a celite plug and washing through with hot EtOH (1 l). The filtrate was concentrated and then separated between EtOAc (100 ml) and saturated Na 2 CO 3 solution (100 ml). The aqueous layer was reextracted with EtOAc (3 × 100 ml). The organics were combined and a precipitate formed. This was filtered and dried to give E2 as a light yellow powder (3.89 g; 45% Preparation of 2-phenylpyrimidine-5-carbonyl chloride Phenylpyrimidine-5-carboxylic acid [101] (500 mg 2.5 mmol) and thionyl chloride (5 ml) were heated under ref lux overnight under an atmosphere of nitrogen. The solvent was removed under reduced pressure and the residue azeotroped with toluene (2 × 10 ml).
E3 (370 mg; 1.6 mmol) was mixed with 2-phenylpyrimidine-5-carbonyl chloride (520 mg; 2.41 mmol) in pyridine (5 ml) and heated at 60°C for 48 h. The reaction mixture was then concentrated in vacuo and the residue was separated between EtOAc (20 ml) and saturated Na 2 CO 3 solution (30 ml). The aqueous layer was further extracted with EtOAc (3 × 25 ml) and the organics were combined and dried (Na 2 SO 4 ), filtered and concentrated to give an orange solid, which was taken up in boiling EtOH and filtered to give 34 as an off white powder (176 mg, 27%). 
In vitro Tc assay for determination of IC 50
This assay uses Tc Tulahuen trypomastigotes (Tc VI) expressing the b-galactosidase gene, obtained from F Buckner (University of Washington, WA, USA) and was performed according to the published protocol [24] and as previously reported [14] . Tc compound compound only 100
For each compound, percentage inhibition values were used to generate a standard curve from which the IC 50 was calculated. Each assay was performed on two plates and the average was used.
In vitro assay for determination of cytotoxicity in L6 cells Assay methods were as previously described [14] .
In vitro T. b. rhodesiense assay for determination of IC 50
Assay methods were as previously reported [25] .
In vitro L. infantum assay for determination of IC 50 L.infantum MHOM/MA(BE)/67 amastigotes were collected from the spleen of an infected donor hamster and used to infect primary peritoneal mouse macrophages. Drug sensitivity assays were performed in 96-well microtiter plates, each well containing 10 µl of the compound dilutions together with 190 µl of macrophage/parasite inoculum (3 × 10 4 cells + 4.5 × 10 5 parasites/ well). The inoculum was prepared in RPMI-1640 medium, supplemented with 200 mM l-glutamine, 16.5 mM NaHC0 3 and 5% inactivated fetal calf serum. The macrophages were infected after 48 h. The compounds were added after 2 h of infection. Parasite multiplication is compared with untreated-infected controls (100% growth) and uninfected controls (0% growth). After 5 days incubation, parasite burdens (mean number of amastigotes/macrophage) are microscopically assessed after staining the cells with a 10% Giemsa solution. The results are expressed as percentage reduction in parasitic burden compared with untreated control wells and an IC 50 is calculated.
In vitro assay for determination of cytotoxicity on human fibroblasts (MRC-5 cell line)
The compounds are tested at five concentrations. Assays were performed in sterile 96-well microtiter plates, each well containing 10 µl Step 1
Step 2
Step 3
Step 4 diluted compound together with 190 µl of MRC-5 SV2 inoculum (3 × 10 4 cells/ml). Cell growth is compared with untreated-control wells (100% cell growth) and medium-control wells (0% cell growth). After 3 days of incubation, cell viability is assessed f luorimetrically after addition of 50 µl resazurin per well. After 4 h at 37°C, fluorescence is measured (lex 550 nm, lem 590 nm). The results are expressed as percentage reduction in cell growth/viability compared with control wells and an IC 50 is determined.
E1
In vitro assays for determination of solubility, microsomal stability & inhibition of cytochrome P450 3A4 Assay methods were as previously described [14] .
Determination of LogD
Partition coefficient values (LogD) of the test compounds were estimated by correlation of their chromatographic retention properties against the characteristics of a series of standard compounds with known partition coefficient values, at pH 7.4. The method employed is a gradient HPLC-based derivation of the method developed by Lombardo [26] .
In vivo pharmacokinetic studies Pharmacokinetic studies in mice were performed in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes and the study protocols were approved by the Monash Institute of Pharmaceutical Sciences Animal Ethics Committee. The systemic exposure of compounds 34, 40, 42 and 56 was assessed following oral administration in non-fasted male Swiss outbred mice weighing 24-31 g using an abbreviated sampling schedule. Mice had access to food and water continuously throughout the pre-and post-dose phases of the study. Compounds were administered orally by gavage as either a solution or suspension in an aqueous vehicle (0.2 ml dose volume per mouse). At predefined time points, blood samples were collected from mice (n = 2 mice per time point for each compound) via either submandibularbleed (conscious sampling) or terminal cardiac puncture (following anaesthetization with gaseous isoflurane). Blood was transferred to heparinized tubes containing a stabilization cocktail (complete protease inhibitor cocktail [Hoffmann-La Roche Ltd], potassium fluoride and EDTA) to minimize the potential for ex vivo degradation of compound. Samples were immediately centrifuged to collect plasma for ana lysis. Compound concentrations in plasma were quantitated by LC-MS (on a Micromass Xevo TQ coupled to an Acquity UPLC; both from Waters Corporation, MA, USA) against calibration standards prepared in blank mouse plasma. Both samples and standards were prepared by precipitation with acetonitrile, followed by centrifugation and ana lysis of the supernatant. The analytical lower limit of quantitation for each compound in plasma ranged from 0.001 to 0.015 µM.
In vivo Tc efficacy model Outbred, female Swiss mice approximately 8 weeks old were obtained from the Animal Resources Centre (Perth, Western Australia). All animal experimentation was carried out with approval of the Animal Ethics Committee of Murdoch University. Tc parasites (Tulahuen Tc VI) were passaged through adult female Swiss mice to maintain virility. Trypomastigote-infected blood was collected and frozen in liquid nitrogen for subsequent infections in mice. In vivo toxicity testing Compounds were first screened in an in vivo mouse toxicity assay before evaluation for efficacy in the Tc subchronic infection model. For toxicity testing, compounds were prepared in vehicle at concentrations of 15 mg/ ml. Two mice were used for each assessment, with each mouse receiving a cumulative dose of up to 200 mg/kg (34 50 mg/kg dose q.d.) and 600 mg/kg (34 20 mg/kg dose b.i.d.) over a period of 48 h. Mice were observed for 1 week following the last dose and no adverse effects or weight-loss was noted in this experiment.
In vivo efficacy testing As previously described [14] , except mice were infected intraperitoneally with 40,000
Selection & optimization of hits from a high-throughput phenotypic screen against T. cruzi | ReseaRch aRticle www.future-science.com bloodform trypomastigotes of Tc (Tulahuén Tc VI). Five mice per group. Compound dosing was commenced on day 8 postinfection. Groups were scheduled to receive either 34 or benznidazole in an oral dose given either q.d. or b.i.d. for 20 days, with the last dose being received on day 27 postinfection Doses were administered by oral gavage in volumes of 200 µl. Blood parasitemia levels were evaluated over the course of the 20 days dosing by pricking the tail and collecting 3 µl of blood, which was diluted 1:10 with red blood cell lysis and counted under the microscope using a neubauer hemocytometer. If parasitemia levels were no longer detectable in blood following compound treatment, cyclophosphamideinduced immunosuppression was commenced 10 days after cessation of dosing. Cyclophosphamide was administered by intraperitoneal injection at 50 mg/kg per day in three cycles, each cycle comprised 4 days treatment followed by three days rest. Parasitemia was determined by collection of blood by tail prick as detailed above. The absence of parasites from organs was confirmed by conducting PCR on tissue samples (spleen, heart, skeletal muscle and colon) and blood.
Discussion
Robust, phenotypic whole organism assays are well established in high-throughput format for screening large compound collections against Tc [24, 27, 28] and HAT [29] , compensating for the limited availability of validated targets amenable to drug screening in the kinetoplastid field [30] . In recent years, access to pharmaceutical company compound collections has improved to provide a larger pool of starting hits to evaluate [205] . A phenotypic screen identifies all active compounds by not restricting hits to one particular mechanism of action and is very useful for opportunistic screening of compound diversity sets [31] . A functional whole-cell assay selects for cell permeable hits and avoids potential downstream disconnects between in vitro activity and in vivo efficacy screens that may arise when SAR studies are driven by a target-based assay. Knowledge of the biochemical target can be useful during the later stages of lead optimization to assess target selectivity, especially if a human ortholog exists for example.
The hit triage process described herein was relatively subjective and other teams have approached the hit set differently [32] . The emphasis on a rapid evaluation strategy permitted the synthesis of tractable targets only and this is normally sufficient to get a reasonable understanding of the scope of an SAR to make a go or no-go decision. Gaps in the SAR are an unavoidable disadvantage of the approach, but hits can be revisited in a followup effort if required. Hit assessment was performed in parallel, where resources permitted, to aid termination decisions. This prevents hits persisting for longer than is necessary if others are progressing faster. The requirement for commercial availability most likely eliminated potentially interesting compounds and a review of the hit data set with the knowledge that has been acquired, may provide a different perspective on the merits of hit resynthesis.
The attrition rate following hit assessment was high with four hits from 123 progressing into extended SAR investigations. Two series, CM74 and CM100, are currently in Tc inhibitor lead optimization programs. Molecules in these series have very potent in vitro activities, Tc IC 50 < 10 nM, with a subsection of analogs < 1 nM. How effectively this activity translates into in vivo efficacy will be dependent on the successful optimization of physicochemical and pharmacokinetic parameters, but high target potency should aid selectivity and overcome suboptimal solubility to a certain extent. Compounds in the CM74 and CM100 series are not cytotoxic in vitro and no adverse reactions or compound-related side effects were observed after reaching cumulative concentrations of up to 600 mg/kg following oral administration over 2 days, an assessment made prior to in vivo efficacy studies. Compounds in both series have drug-like in vitro profiles with the exception of solubility and, for some analogs, cross-reactivity with P450 enzyme CYP3A4. Improved solubility is a current focus of the ongoing optimization process. More extended selectivity and safety profiling will take place in due course.
Acceptable plasma concentrations in mice following oral administration of a 20 mg/kg dose advanced lead compounds from the CM100 series into in vivo efficacy studies, to determine the extent of parasitemia reduction in a subchronic model of Tc infection. Compounds 34, 40, 42 and 56 were each able to reduce parasitemia to negligible levels after 20 days dosing at 20 mg/kg q.d., but parasites re-emerged in blood before experiment end. To overcome any deficiency in compound half-life in mice, the experiment was repeated with 34 under different dosing regimens. When dosed at 20 mg/kg b.i.d., a more robust response was recorded with 60% of the mice being parasite free in blood until day 60 (experiment end) even after three cycles of immunosuppression. These results suggest that maintaining adequate blood concentrations over the full dosing interval is necessary for efficacy. PCR ana lysis detected parasites in all three of the remaining mice, but not in all tissue samples (skeletal muscle n = 1; spleen n = 1; colon n = 2). Although not considered to be a cure, this was a very important and successful outcome with regard to proof-of-concept for the new series. Benznidazole was used as a positive control and dosed at 100 mg/kg q.d. Under these conditions, 80% of mice in this group reached experiment end, but were not cured as determined by PCR ana lysis. Additional ongoing in vitro and in vivo pharmacokinetic studies will aid CM100 series compound optimization specifically targeted at improving the in vivo efficacy. A large volume of distribution and a long terminal half-life are two key parameters identified for optimization of anti-Chagasic drugs [33, 34] . Compounds with these attributes should distribute more effectively into tissues for greater efficacy in later stages of the disease.
With regard to the topic of chemodiversity within the Tc discovery portfolio and a primary driver behind investigating hits from a phenotypic screen, we consider whether we have increased structural or mechanistic novelty, or both? For structure, this is not especially evident. Several imidazole-containing Tc inhibitors at the hit development stage and structurally related to CM74 and CM100 have been reported recently [35] [36] [37] [38] . Although these compounds were discovered by different screening methods to the assay discussed herein, it is interesting that activity data led us towards imidazole compounds even though we started with a diverse set of structures to evaluate. However, the mechanistic implications of this similarity are not necessarily clear cut. Literature imidazoles are reported to inhibit Tc CYP51 [35, 38] , Tc iron superoxide dismutase [37] and to be of unknown mechanism of action [36] . Furthermore, a hit evaluated for malaria identified from screening the Tres Cantos Anti-Malarial Set [39, 40] is very closely related to compounds in the CM100 series. This hit was a highly potent in vitro inhibitor of Plasmodium falciparum and orally active in a nonmyelo-depleted P. falciparum mouse model. P. falciparum does not contain any P450 enzymes [41] further muddying the mechanistic waters and perhaps suggestive of more than one mechanism of action amongst the Tc imidazole-comprized inhibitors. The authors have initiated mechanism of action studies on their lead series and the results will be reported in due course.
Conclusion
Two promising new series of Tc inhibitors have been discovered from the evaluation of over 1600 hits identified by a HTS using a whole organism, phenotypic assay. Compounds in each series are highly active in vitro and are not cytotoxic. The strategies driving the SAR investigations were focused on designing molecules suitable for in vivo efficacy proofof-concept experiments as well as activity optimization. Lead compounds in each series have good drug-like properties as assessed by physicochemical and in vitro metabolism assays, and acceptable concentrations in plasma have been obtained following oral administration to mice. Lead compound 34 from the CM100 series showed very promising efficacy in a subchronic, immunosuppressive mouse model of Tc infection. 60% of mice survived parasite free in blood until the experiment end (day 60) following b.i.d. treatment for 20 days, but were not cured as determined by PCR ana lysis of selected tissues. Alongside further profiling in standard drug development selectivity and safety screens, additional broader profiling of the new Tc inhibitors will take place to assess morph ological changes in the parasite upon compound treatment, rate of kill and effectiveness against different Tc strains to help secure clinical effectiveness. The results of studies relating to other Tc inhibitor hits in the public domain have been presented to facilitate the efforts of fellow researchers in the field. Crossplatform screening against two other kinetoplastid targets of a structurally representative cross-section of analogs prepared during the HTS follow up have provided hits for HAT and Leishmaniasis for further development.
Future perspective
New molecules are valuable commodities in the fight against neglected diseases. Screening of large compound libraries built up over many years in the pharmaceutical sector will hopefully inject some badly needed chemodiversity into Selection & optimization of hits from a high-throughput phenotypic screen against T. cruzi | ReseaRch aRticle www.future-science.com the trypanosomatid drug discovery portfolio, allowing researchers access to previously unexplored areas of chemical space for these targets. However, additional challenges still remain. The operational difficulty of in vitro phenotypic screening against many of the causative agents of neglected diseases has slowed down research immensely. Breakthroughs in assay development have, and will continue to accelerate discovery efforts. Furthermore, the ability to profile multiple parasite strains must become easier and more mainstream to aid the development of treatments for a geographically wide-spread patient base and for patients with mixed infections. As early discovery phase opportunities gain momentum, feedback from clinical evaluation of drugs new to the field is eagerly anticipated. This will be useful to validate discovery flow schemes and highlight knowledge gaps. Of particular importance to Chagas disease research is the clinical validation of discovery phase in vivo efficacy models and their use in developing pharmacokinetic/pharmacodynamic relationships. The development of biomarkers that allow for effective evaluation of clinical cure is a critical need. Collabo ration, communal access to data, and expertise-and resourcesharing will be the driving forces behind success in this emerging field, and may represent a new paradigm for drug discovery. 
Supplementary data
Executive summary
Background High-throughput screening is a valuable method to inject chemodiversity into the trypanosomatid drug discovery portfolio.
Hit evaluation & lead optimization
Multiple screen hits from a high-throughput screening targeting Trypanosoma cruzi inhibition were evaluated through a rapid hit assessment process, leading to the development of two series that potently and selectively inhibit T. cruzi in vitro.
In vivo efficacy
Lead T. cruzi inhibitor 34 has a pharmacokinetic profile suitable for oral dosing and successfully reduced blood-borne parasitemia to undetectable levels in a proof-of-concept efficacy study in T. cruzi-infected mice.
Additional screening
Cross-platform screening against other trypanosomatid targets identified hits for Human African trypanosomiasis and leishmaniasis that are under evaluation.
Ongoing studies
Further optimization and broader profiling of the two lead T. cruzi inhibitor series, including mechanism of action studies, is ongoing.
